Cortechs.ai | The importance of a 3D T1 sequence

The importance of a 3D T1 sequence

In this post, I explore why NeuroQuant processing uses a 3D T1 sagittal MRI sequence and that using other sequences will generate an unsupported MR sequence error message.

Previously, I reviewed how to ensure accurate NeuroQuant processing results, and my colleague discussed why contrast agents are not used to achieve quality segmentation with NeuroQuant, and examined why good alignment to atlas is necessary for accurate NeuroQuant output.

3D T1 sagittal MRIs are needed to obtain ideal brain morphometry for volume analysis. In order to achieve its high-quality segmentation results, NeuroQuant has been optimized for processing 3D T1 sagittal MRI acquisition sequence in 1.2, 1.5 and 3.0T scanners.

As a quality control feature, NeuroQuant contains a data filtering mechanism that provides verification of study scanning parameters prior to initiating processing. Ensuring proper processing preserves the accuracy of the segmentation results and therefore, the accuracy of the calculated brain volumes. To protect the accuracy of the results, NeuroQuant prevents analysis when sequences other than 3D T1 are sent for processing.

The unsupported sequences provided as examples below will generate an error message.

unsupported_seq.png

Another example that will generate an error message happens when the wrong series (or entire exam) is sent. When an entire exam is sent instead of just the required 3D T1 NeuroQuant scan, there can be a  delay in the return of NeuroQuant results, which will result in multiple error messages being sent back to the PACS.

More information about using and processing NeuroQuant can be found here.

More Resources

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.

02/11/2026

NeuroQuant Normative Database: Advancing Age‑ and Sex‑Specific Brain Volumetry

Learn how the latest updates to the NeuroQuant normative database white paper strengthen age- and sex-specific brain volumetry and enhance clinical confidence.
Scroll to Top